| 000 | 00902 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250511181504.0 | ||
| 264 | 0 | _c19930128 | |
| 008 | 199301s 0 0 eng d | ||
| 022 | _a0959-8138 | ||
| 024 | 7 |
_a10.1136/bmj.305.6863.1225-b _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBarrett, P J | |
| 245 | 0 | 0 |
_aEcstasy and dantrolene. _h[electronic resource] |
| 260 |
_bBMJ (Clinical research ed.) _cNov 1992 |
||
| 300 |
_a1225 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 |
_a3,4-Methylenedioxyamphetamine _xadverse effects |
| 650 | 0 | 4 |
_aDantrolene _xadverse effects |
| 650 | 0 | 4 |
_aDesigner Drugs _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aN-Methyl-3,4-methylenedioxyamphetamine |
| 773 | 0 |
_tBMJ (Clinical research ed.) _gvol. 305 _gno. 6863 _gp. 1225 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/bmj.305.6863.1225-b _zAvailable from publisher's website |
| 999 |
_c1367888 _d1367888 |
||